Can Antidepressants Curb Domestic Violence? A Critical Look at the ReINVEST Trial

The question of whether a common antidepressant could mitigate domestic violence is a provocative one. A recently published study in The Lancet eClinicalMedicine – the ReINVEST trial – suggests there might be a connection, sparking conversations among experts and policymakers alike. The research, conducted over a decade by UNSW and the University of Newcastle, explores whether sertraline, a widely used antidepressant, could be a tool in reducing domestic violence reoffending.

The core finding? The ReINVEST trial saw a significant decrease in domestic violence offenses at the 24-month mark, observing a 21% risk reduction in participants taking sertraline compared to those on a placebo. Even more promising, men who adhered more closely to their medication regimen saw a 30% drop in reoffending. For those with high psychological distress, the reduction was a striking 52%.
>

These numbers certainly grab attention. Yet, it’s wise to approach such results with measured optimism. This wasn’t just about handing out pills. Participants received comprehensive support from mental health professionals. It’s difficult to isolate the drug’s impact from the intensive support these men received. Did the sertraline genuinely reduce violent behavior, or did it simply make participants more receptive to the therapy and support offered? This support likely boosted adherence to the trial and reduced incidents.

It’s worth recalling the intense criticism the ReINVEST trial faced early on. Some women’s advocates and politicians voiced safety concerns and questioned the allocation of government funding, particularly given the chronic underfunding of victim support services. To understand the sector’s hesitations, one must consider the complexity and severity of domestic violence. Skepticism around a “quick fix” is understandable.

Professor Troy McEwan from Swinburne University emphasizes the study’s methodological rigor, a factor often lacking in domestic violence intervention research. He notes that the impact on reoffending appears to be larger than what’s typically observed in evaluations of men’s behavior change programs. Still, it’s crucial to acknowledge that this is one study, and further research will be essential.
>

The premise behind ReINVEST lies in the link between impulsivity, aggression, and serotonin levels. The researchers hypothesized that sertraline, an SSRI, could help regulate impulsivity and, as a result, lower the propensity for violence. The study involved 630 men in NSW, carefully screened from a pool of 1,738, with roughly half receiving sertraline and half a placebo. Safety was established with fewer events in the treatment group (6.9%) than the placebo group (9.3%).

That said, participant drop-out was a challenge. Recruiting and retaining individuals prone to conflict and distrust of authority is not easy. Securing eight years for participant recruitment highlights this issue.

Interestingly, the trial didn’t demonstrate a reduction in general violent offending, only domestic violence. The research team suggests that domestic violence may be more emotionally reactive than premeditated violence. A stickup for example, differs from the heat-of-the-moment anger that can fuel domestic abuse.

Lee Knight, ReINVEST’s clinical coordinator, highlights the necessity of wraparound support. A prescription alone likely wouldn’t yield the same results, considering compliance challenges within this population. It points to the need for a holistic approach rather than relying solely on medication.

A common critique of this kind of research is whether it risks excusing abusers by framing violence as a failure of impulse control. It’s a valid point. No one is suggesting impulsivity justifies violence. Violence, Knight emphasizes, is a choice, and clinicians worked to instill better coping mechanisms in participants.

However, Professor McEwan rightly points out that ignoring individual vulnerabilities, like trauma or mental illness, will doom intervention attempts. Tailoring interventions to the reasons behind the violence is essential. Blindly attributing all violence to broad societal factors like gender inequality risks oversimplifying a multifaceted issue.

Professor Michael Salter from UNSW, though not involved in the study, acknowledges the potential for SSRIs to modulate emotions and reduce violence in certain individuals. He notes the resistance to viewing domestic violence through a men’s health lens, a perspective he feels is gaining traction. To that end, Salter suggests that the ReINVEST results offer a signal for health departments, in addition to justice departments. He advocates for a multi-sectoral response that integrates health services as a point of access for relevant interventions.

The ReINVEST team now aims to extend the trial into a continuing service and delve deeper into understanding the nuances of domestic violence and the potential for SSRIs to assist particular subgroups of offenders. They hope this research will inform governmental strategies and funding decisions.

Despite the positive findings, the team’s journey wasn’t without adversity. Following earlier reporting, the trial was labeled “dangerous”. Methodological issues were also raised, such as the undercounting of domestic violence due to underreporting. A government official’s comment dismissing further funding as “throwing good money after bad” further complicated matters.

Professor Butler reflects that many claims made against the trial were simply false. The team’s data indicated they provided significant support to women. The final results may speak for themselves. Butler expresses that the team feels justified for pursuing their line of treatment. Also, he hopes for domestic violence to be a treatable mechanism.

Looking ahead, the insights from the ReINVEST trial present an opportunity to consider fresh approaches to addressing domestic violence. It might be that a combination of medication, therapy, and robust support systems can offer a pathway to change for some perpetrators. The challenge now lies in translating these findings into practical strategies. This requires careful consideration, ongoing evaluation, and a commitment to evidence-based practices.

Read Original

Keywords: antidepressants, domestic violence, ReINVEST trial, sertraline, domestic violence reoffending, SSRIs, mens health, violence intervention